Literature DB >> 26916007

Hsp90: A Global Regulator of the Genotype-to-Phenotype Map in Cancers.

Daniel Jarosz1.   

Abstract

Cancer cells have the unusual capacity to limit the cost of the mutation load that they harbor and simultaneously harness its evolutionary potential. This property fuels drug resistance, a key failure mode in oncogene-directed therapy. However, the factors that regulate this capacity might also provide an Achilles' heel that could be exploited therapeutically. Recently, insight has come from a seemingly distant field: protein folding. It is now clear that protein homeostasis broadly supports malignancy and fuels the rapid evolution of drug resistance. Among protein homeostatic mechanisms that influence cancer biology, the essential ATP-driven molecular chaperone heat-shock protein 90 (Hsp90) is especially important. Hsp90 catalyzes folding of many proteins that regulate growth and development. These "client" kinases, transcription factors, and ubiquitin ligases often play critical roles in human disease, especially cancer. Studies in a wide range of systems-from single-celled organisms to human tumor samples-suggest that Hsp90 can broadly reshape the map between genotype and phenotype, acting as a "capacitor" and "potentiator" of genetic variation. Indeed, it has likely done so to such a degree that it has left an impress on diverse genome sequences. Hsp90 can constitute as much as 5% of total protein in transformed cells and increased levels of heat-shock activation correlate with poor prognosis in breast cancer. These findings and others have motivated a flurry of interest in Hsp90 inhibitors as cancer therapeutics, which have met with rather limited success as single agents, but may eventually prove invaluable in limiting the emergence of resistance to other chemotherapeutics, both genotoxic and molecularly targeted. Here, we provide an overview of Hsp90 function, review its relationship to genetic variation and the evolution of new traits, and discuss the importance of these findings for cancer biology and future efforts to drug this pathway.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer therapeutics; Chaperone; Disease evolution; Epigenetics; Hsp90; Protein folding

Mesh:

Substances:

Year:  2015        PMID: 26916007     DOI: 10.1016/bs.acr.2015.11.001

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  19 in total

1.  Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus.

Authors:  Zhigang Chen; Thomas L Eggerman; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Roger Kurlander; Amy P Patterson
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

Review 2.  The Multifaceted Role of HSF1 in Tumorigenesis.

Authors:  Milad J Alasady; Marc L Mendillo
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  Stress-Induced Mutagenesis: Implications in Cancer and Drug Resistance.

Authors:  Devon M Fitzgerald; P J Hastings; Susan M Rosenberg
Journal:  Annu Rev Cancer Biol       Date:  2017-03

Review 4.  Decanalizing thinking on genetic canalization.

Authors:  Kerry Geiler-Samerotte; Federica M O Sartori; Mark L Siegal
Journal:  Semin Cell Dev Biol       Date:  2018-05-24       Impact factor: 7.727

5.  Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

Authors:  Sanket J Mishra; Suman Ghosh; Andrew R Stothert; Chad A Dickey; Brian S J Blagg
Journal:  ACS Chem Biol       Date:  2016-12-13       Impact factor: 5.100

Review 6.  Mutations, protein homeostasis, and epigenetic control of genome integrity.

Authors:  Jinglin Lucy Xie; Daniel F Jarosz
Journal:  DNA Repair (Amst)       Date:  2018-08-23

7.  Selection Transforms the Landscape of Genetic Variation Interacting with Hsp90.

Authors:  Kerry A Geiler-Samerotte; Yuan O Zhu; Benjamin E Goulet; David W Hall; Mark L Siegal
Journal:  PLoS Biol       Date:  2016-10-21       Impact factor: 8.029

8.  Retrospective Proteomic Screening of 100 Breast Cancer Tissues.

Authors:  Ida Pucci-Minafra; Gianluca Di Cara; Rosa Musso; Patrizia Cancemi; Nadia Ninfa Albanese; Elena Roz; Salvatore Minafra
Journal:  Proteomes       Date:  2017-07-07

9.  NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo.

Authors:  Jianpo Lian; Dengqiang Lin; Xing Xie; Yunze Xu; Lieyu Xu; Li Meng; Yu Zhu
Journal:  Onco Targets Ther       Date:  2017-04-19       Impact factor: 4.147

10.  The Molecular Chaperone HSP90 Promotes Notch Signaling in the Germline of Caenorhabditis elegans.

Authors:  James L Lissemore; Elyse Connors; Ying Liu; Li Qiao; Bing Yang; Mark L Edgley; Stephane Flibotte; Jon Taylor; Vinci Au; Donald G Moerman; Eleanor M Maine
Journal:  G3 (Bethesda)       Date:  2018-05-04       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.